Blaze Bioscience has raised $9 million to further its development of its first product designed to illuminate cancer cells during surgery.

The financing, mostly from previous investors, brings the Seattle biotechnology company’s total funding since 2010 to $19 million.

The company says its product candidate BLZ-100, the first using a technology it calls Tumor Paint, can assist surgeons in removing solid tumors by making cancer cells visible with a fluorescent dye.